Liora M. Schultz

Palo Alto University — United States

Medicine · Health Sciences

22h-index4.4kcitations143works5.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(104), Acute Lymphoblastic Leukemia research(30), Viral Infectious Diseases and Gene Expression in Insects(17), Virus-based gene therapy research(13), Immune Cell Function and Interaction(13)

Publications142 total

Interpreting Next-Generation Immunosequencing Results in Children and Young Adults with Acute Lymphoblastic Leukemia
Blood Advances·2026Open Access
Validation of a Pre-Infusion Prediction Model for IEC-HS in Children and Young Adults with B-Acute Lymphoblastic Leukemia
Transplantation and Cellular Therapy·2026
Phase II One Arm Multicenter Study of Early Reinfusion of Tisagenlecleucel to Promote Durable B-cell Aplasia in Pediatric and Young Adult Patients with relapsed/refractory CD19-Positive B-cell Acute Lymphoblastic Leukemia (REFUEL)
Transplantation and Cellular Therapy·2026Open Access
The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer
Nature Reviews Clinical Oncology·2026
Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Blood Cancer Discovery·2025Open Access
CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity
Blood·2025Open Access
Peripheral blast count at apheresis as a risk factor for survival following tisagenlecleucel in children and young adults
Blood·2025Open Access
Pre-CAR next generation sequencing informs patient outcomes in children and young adults with B-acute lymphoblastic leukemia
Blood·2025
Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results
Blood·2025Open Access
Pre-transplant CAR T-cell therapy is associated with inferior survival and increased non-relapse mortality in pediatric B-ALL: A single-center retrospective analysis
Blood·2025
269 Humanized anti-CAR antibodies affect durable response to GD2-CAR T-cells in diffuse midline glioma
Regular and Young Investigator Award Abstracts·2025Open Access
Harmonization on defining B‐cell recovery post CD19‐CAR T‐cell therapy in B‐cell acute lymphoblastic leukemia: An international consensus statement
HemaSphere·2025Open Access
CTIM-05. HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA
Neuro-Oncology·2025Open Access
LocaTIAN, locaTIAN, locaTIAN
Blood·2025Open Access
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies
Cytotherapy·2025Open Access
Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell Providers
Transplantation and Cellular Therapy·2025· 3 citedOpen Access
Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel
Blood Advances·2025Open Access
Impact of CAR T cell therapy on thymus size in children and young adults with acute lymphoblastic leukemia
Scientific Reports·2025· 1 citedOpen Access
Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel
Blood Advances·2025· 1 citedOpen Access
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy
Blood Advances·2025· 4 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Christina Baggott(23), Kara L. Davis(20), Crystal L. Mackall(19), Bita Sahaf(18), Sneha Ramakrishna(17), Sharon Mavroukakis(16), Emily Egeler(16), Shabnum Patel(15), Steven A. Feldman(15), Michael Kunicki(14), Snehit Prabhu(14), Robbie G. Majzner(13), Crystal L. Mackall(12), Harshini Chinnasamy(11), Vanessa A. Fabrizio(11), Jenna Rossoff(11), Amy Moskop(11), Nicole Karras(11), Theodore W. Laetsch(11), Kevin J. Curran(11)